Xenetic Biosciences, Inc. (XBIO) stock
XBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3067% below fair value
$1.61+0.12 (+8.05%)
Close on Nov 17, 2026Market cap $3.77MP/E –Yield –
Xenetic Biosciences gross margin
Gross margin is gross profit as a percentage of revenue.
For fiscal 2013 it was 100.0%, against 84.7% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | 100.0% | +15.3 |
| FY2012 | Dec 31, 2012 | 84.7% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2017 | Sep 30, 2017 | -14.2% | – |
See a number that looks wrong?